Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...
GSK (LSE:GSK) has licensed worldwide rights to its experimental liver disease drug linerixibat to Alfasigma. The agreement ...
A major pharmaceutical company is leaving behind more than half a million square feet in a suburb of Washington, D.C. when its lease expires next year. London-based GSK is set to depart 635,000 square ...
GSK (LSE:GSK) has completed its acquisition of RAPT Therapeutics, securing global rights to key immunology assets. The deal brings ozureprubart, a monoclonal antibody for severe food allergies, into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results